Clinical trials
catalyst calendar across sponsors →Studies where FHTX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
Held by 7 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, Qube Research & Technologies Ltd, CITADEL ADVISORS LLC, Squarepoint Ops LLC, AQR CAPITAL MANAGEMENT LLC, +2 more) · FINRA short interest 7.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic MalignanciesNCT04891757Incidence of AEs, dose-limiting toxicities (DLTs), serious AEs (SAEs), AEs leading to discontinuation, and adverse events of special interest (AESIs); safety laboratory assessmentsNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: FHD-286, Low Dose Cytarabine, Decitabine | Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Relapsed Myelodysplastic Syndromes, Refractory Myelodysplastic Syndromes, Relapsed Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia | 144 | Sep 2025 | 2025-07-10 |
| FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss TumorsNCT04965753Incidence of treatment-emergent adverse events (TEAEs)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision | Drug: FHD-609 | Advanced Synovial Sarcoma | 55 | 2023-12-04actual | 2025-03-04 |
| FHD-286 in Subjects With Metastatic Uveal MelanomaNCT04879017Incidence of treatment-emergent adverse events (TEAEs)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor terminated the study for business reasons. | Drug: FHD-286 | Metastatic Uveal Melanoma | 76 | 2023-11-30actual | 2024-04-25 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19